Objective To study the reproductive health status among unmarried floating females in Dongguan city. Methods A self-administered questionnaire was used to collect the information about reproductive health among unmarried floating females in the department of gynaecology and obstetrics and department of dermatology and venerology of 5 general hospitals in Dongguan city. Results Premarital sexual behavior, gynecological diseases, sexually transmitted diseases were reported in 23.71%, 35.11% and 5.41% of 3509 young women. The prevalence of sexual behavior, vaginitis and cervicitis was significantly higher in senior group (>24 years old)than those in junior group (=24 years) (26.39% vs 21.16%; 21.25% vs 17.93%; 8.99% vs 6.85%), but the induced abortion rate in junior group was superior to that in senior group (32.50% vs 23.72%). The morbidity of vaginitis, pelvic inflammatory disease and menoxenia increased remarkably in the females with sexual behavior compared with those without sexual behavior (29.33% vs 16.51%; 7.21% vs 1.16%; 16.47% vs 1.53%). Conclusions There exists a high prevalence of premarital sexual behavior among the unmarried floating females in Dongguan city. Premarital sexual behavior reinforces the risk of sexually transmitted diseases and other genital disorders.

Objective:To explore the arsenic trioxide (As 2O 3)-induced apoptosis of human neuroblastoma cells (SH-SY5Y cells) and the protection mechanisms of folic acid (FA) and vitamin B 12 (VB 12). Methods:SH-SY5Y cells were cultured in vitro and divided into six groups by group design: control group (normal cultured), arsenic exposed group (10.00 μmol/L As 2O 3), FA intervention group (0.30 mmol/L FA + 10.00 μmol/L As 2O 3), VB 12 intervention group (0.06 mmol/L VB 12 + 10.00 μmol/L As 2O 3), combined intervention group (0.30 mmol/L FA + 0.06 mmol/L VB 12 + 10.00 μmol/L As 2O 3) and reagent control group (0.30 mmol/L FA + 0.06 mmol/L VB 12). Cells in each group were cultured for 24 h ( n = 3). Flow cytometry was used to determine the apoptosis rate of cells in each group. Transmission electron microscopy was used to observe the ultrastructural changes of the cells. The expression levels of mRNA and protein of apoptosis-related indicator B-cell lymphoma-2 (Bcl-2) and Bcl-2 associated X (Bax) were detected by fluorescence quantitative PCR and Western blotting. The activity of cysteinyl aspartate specific proteinase (Caspase) 3 was detected by luminescent assay. The above indicators were statistically analyzed. Results:There was statistically significant difference in the apoptosis rate among different groups ( F = 213.036, P < 0.05). The apoptosis rate in arsenic exposed group [(44.43 ± 3.54)%] was higher than that in control, FA intervention, VB 12 intervention, and combined intervention groups [(1.80 ± 0.06)%, (14.37 ± 0.13)%, (19.10 ± 1.56)%, (17.11 ± 2.34)%, P < 0.05]. Under transmission electron microscope, the apoptotic bodies, mitochondria swelling and degeneration, chromatin agglutination were observed in SH-SY5Y cells exposed to arsenic. The morphological and organelle changes of SH-SY5Y cells were significantly improved after respective and combined intervention of FA and VB 12. The expression levels of Bcl-2, Bax mRNA and protein were significantly different among different groups ( F = 5.178, 7.169, 6.142, 9.194, P < 0.05). The expression level of Bcl-2 protein in arsenic exposed group was lower than that in control group ( P < 0.05), and the expression levels of Bax mRNA and protein were higher than those in control group ( P < 0.05). The expression levels of Bcl-2 mRNA and protein in FA intervention group and combined intervention group were higher than those in arsenic exposed group ( P < 0.05), and Bcl-2 mRNA expression level in VB 12 intervention group was higher than that in arsenic exposed group ( P < 0.05). The expression levels of Bax mRNA and protein in FA intervention, VB 12 intervention and combined intervention groups were lower than those in arsenic exposed group ( P < 0.05). There were statistically significant differences in Caspase 3 activity among different groups ( F = 84.604, P < 0.05). Caspase 3 activity in arsenic exposed group was significantly higher than those in control, FA intervention, VB 12 intervention, and combined intervention groups ( P < 0.05). Conclusions:Arsenic exposure can lead to apoptosis and ultrastructural changes of SH-SY5Y cells. FA and VB 12 may effectively inhibit apoptosis through regulating Bcl-2/Bax pathway and decrease Caspase 3 activity, thus playing a protective role on nerve cells.

Objective To investigate the clinical effect of transarterial chemoembolization (TACE) combined with endovascular implantation of iodine-125 seeds in the treatment of primary liver cancer complicated by portal vein tumor thrombus (PVTT) and its influence on liver function. Methods A retrospective analysis was performed for the clinical data of 96 patients with primary liver cancer complicated by PVTT who were admitted to Guangzhou No. 12 People's Hospital from January 2013 to December 2016. Among these patients, 52 were treated with TACE combined with endovascular implantation of iodine-125 seeds in the portal vein (combination group) and 44 were treated with TACE alone (control group) . The two groups were compared in terms of the outcome of tumor lesions and PVTT and the changes in related laboratory markers after treatment. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the control group, the combination group had significantly higher remission rates of tumor lesions (59. 62％ vs 38. 64％, χ2= 4. 196, P = 0. 041) and PVTT (80. 77％ vs 59. 09％, χ2=5. 421, P = 0. 020) . At 8 weeks after surgery, the combination group had significantly lower serum alpha-fetoprotein (AFP), diameter of the main portal vein, and platelet count (PLT) and significantly higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBil) than the control group (t = 3. 891, 3. 291, 2. 330, 3. 729, 3. 582, and 4. 126, all P ＜0. 05); both groups showed significant increases in serum levels of ALT, AST, and TBil (all P ＜ 0. 05) and significant reductions in PLT, serum AFP and diameter of the main portal vein (all P ＜ 0. 05) . Conclusion TACE combined with endovascular implantation of iodine-125 seeds in the portal vein has a better clinical effect than TACE alone in the treatment of primary liver cancer complicated by PVTT, but more attention should be paid to liver impairment during treatment.

OBJECTIVETo investigate the tumor targeting efficacy of (18)F-AlF-NOTA-PRGD2, a novel radiotracer of Arginine-glycine-aspartic acid (RGD) peptides.

METHODS(18)F-AlF-NOTA-PRGD2 was synthesized in one-step by conjugating NOTA-PRGD2 with (18)F-AlF at 100 degrees celsius;. The tumor targeting efficacy and in vivo biodistribution profile of (18)F-AlF-NOTA-PRGD2, following intravenous injection via the tail vein, were evaluated in a nude mouse model bearing subcutaneous U87MG glioblastoma xenograft by radioactivity biodistribution assessment, PET/CT and microPET/CT.

RESULTSNOTA-PRGD2 was (18)F-fluorinated successfully in one-step with a yield of 17%-25% within 15-20 min. Radioactivity biodistribution study confirmed the tumor-targeting ability of (18)F-AlF-NOTA-PRGD2 in the tumor-bearing mice. At 1 and 2 h following injection, (18)F-AlF-NOTA-PRGD2 uptake in the tumor reached 4.14∓1.44 and 2.80∓1.18 % ID/g (t=1.910, P=0.070) with tumor/brain ratios of 2.95∓0.61 and 5.21∓2.62, respectively (t=-1.686, P=0.167). Both PET/CT and microPET/CT were capable of showing the radioactivity biodistribution of (18)F-AlF-NOTA-PRGD2 in the mouse model and clearly displayed the tumor, but microPET/CT showed a much better image quality.

CONCLUSION(18)F-AlF-NOTA-PRGD2 prepared by one-step radiosynthesis can selectively target to the tumor, demonstrating its potential as a good radiotracer for tumor imaging.

Animals ; Cell Line, Tumor ; Fluorine Radioisotopes ; Glioblastoma ; diagnostic imaging ; Humans ; Mice ; Mice, Nude ; Oligopeptides ; Positron-Emission Tomography ; methods ; Radioactive Tracers

Objective To investigate the tumor targeting efficacy of 18F-AlF-NOTA-PRGD2, a novel radiotracer of Arginine-glycine-aspartic acid (RGD) peptides. Methods 18F-AlF-NOTA-PRGD2 was synthesized in one-step by conjugating NOTA-RGD2 with 18F-AlF at 100℃. The tumor targeting efficacy and in vivo biodistribution profile of 18F-AlF-NOTA-RGD2, following intravenous injection via the tail vein, were evaluated in a nude mouse model bearing subcutaneous U87MG glioblastoma xenograft by radioactivity biodistribution assessment, PET/CT and microPET/CT. Results NOTA-RGD2 was 18F-fluorinated successfully in one-step with a yield of 17%-25%within 15-20 min. Radioactivity biodistribution study confirmed the tumor-targeting ability of 18F-AlF-NOTA-PRGD2 in the tumor-bearing mice. At 1 and 2 h following injection, 18F-AlF-NOTA-PRGD2 uptake in the tumor reached 4.14 ± 1.44 and 2.80 ± 1.18%ID/g (t=1.910, P=0.070) with tumor/brain ratios of 2.95 ± 0.61 and 5.21 ± 2.62, respectively (t=-1.686, P=0.167). Both PET/CT and microPET/CT were capable of showing the radioactivity biodistribution of 18F-AlF-NOTA-PRGD2 in the mouse model and clearly displayed the tumor, but microPET/CT showed a much better image quality. Conclusion 18F- AlF- NOTA- PRGD2 prepared by one- step radiosynthesis can selectively target to the tumor, demonstrating its potential as a good radiotracer for tumor imaging.

Objective To investigate the tumor targeting efficacy of 18F-AlF-NOTA-PRGD2, a novel radiotracer of Arginine-glycine-aspartic acid (RGD) peptides. Methods 18F-AlF-NOTA-PRGD2 was synthesized in one-step by conjugating NOTA-RGD2 with 18F-AlF at 100℃. The tumor targeting efficacy and in vivo biodistribution profile of 18F-AlF-NOTA-RGD2, following intravenous injection via the tail vein, were evaluated in a nude mouse model bearing subcutaneous U87MG glioblastoma xenograft by radioactivity biodistribution assessment, PET/CT and microPET/CT. Results NOTA-RGD2 was 18F-fluorinated successfully in one-step with a yield of 17%-25%within 15-20 min. Radioactivity biodistribution study confirmed the tumor-targeting ability of 18F-AlF-NOTA-PRGD2 in the tumor-bearing mice. At 1 and 2 h following injection, 18F-AlF-NOTA-PRGD2 uptake in the tumor reached 4.14 ± 1.44 and 2.80 ± 1.18%ID/g (t=1.910, P=0.070) with tumor/brain ratios of 2.95 ± 0.61 and 5.21 ± 2.62, respectively (t=-1.686, P=0.167). Both PET/CT and microPET/CT were capable of showing the radioactivity biodistribution of 18F-AlF-NOTA-PRGD2 in the mouse model and clearly displayed the tumor, but microPET/CT showed a much better image quality. Conclusion 18F- AlF- NOTA- PRGD2 prepared by one- step radiosynthesis can selectively target to the tumor, demonstrating its potential as a good radiotracer for tumor imaging.

Objective To evaluate the efficacy and safety of Elvitegravir,Cobicistat,Emtricit-abine and Tenofovir Alafenamide Fumarate Tablets in initial treatment of acquired immune deficiency syndrome(AIDS)patients.Methods A total of 80 treatment-naive AIDS patients were selected as research subjects and randomly divided into control group and observation group,with 40 patients in each group.The control group was treated with free antiviral drugs(tenofovir+lamivudine+efa-virenz),while the observation group was treated with Elvitegravir,Cobicistat,Emtricitabine and Teno-fovir Alafenamide Fumarate Tablets.The CD4+count,human immunodeficiency virus(HIV)viral load,and biochemical indicators were compared between the two groups before treatment and at 3,6,9,and 12 months after treatment.The adherence,adverse reactions,and quality of life were also com-pared between the two groups.Results During the treatment,six patients in the observation group and 9 patients in the control group had no compliance.With the extension of treatment time,the CD4+level in both groups gradually increased,and the HIV viral load gradually decreased(P＜0.05).After 3,6,9,and 12 months of treatment,the CD4+levels in the observation group were higher than those in the control group,and the HIV viral loads were lower than those in the control group(P＜0.05).With the extension of treatment time,the levels of alanine aminotransferase,aspartate aminotransferase,urea,creatinine,and uric acid in the control group gradually increased,and the random blood glucose levels after 3,6,9,and 12 months of treatment in the control group were higher than those before treatment(P＜0.05).After 3,6,9,and 12 months of treatment,the lev-els of alanine aminotransferase,aspartate aminotransferase,urea,creatinine,uric acid,and random blood glucose in the observation group were lower than those in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 2.94％(1/34),which was lower than 90.00％(36/40)in the control group(correctedx2=55.718,P＜0.001).With the extension of treatment time,the scores of various dimensions of quality of life in both groups gradually increased,and the scores of various dimensions of quality of life after treatment in the observation group were higher than those in the control group(P＜0.05).Conclusion Compared with the free antiviral drug regimen,Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide Fumarate Tablets shows better efficacy in the treatment of AIDS-naive patients,which can significantly increase the CD4+level,and reduce the HIV viral load.Besides,it has high safety,and can significantly im-prove their quality of life.

Objective To evaluate the efficacy and safety of Elvitegravir,Cobicistat,Emtricit-abine and Tenofovir Alafenamide Fumarate Tablets in initial treatment of acquired immune deficiency syndrome(AIDS)patients.Methods A total of 80 treatment-naive AIDS patients were selected as research subjects and randomly divided into control group and observation group,with 40 patients in each group.The control group was treated with free antiviral drugs(tenofovir+lamivudine+efa-virenz),while the observation group was treated with Elvitegravir,Cobicistat,Emtricitabine and Teno-fovir Alafenamide Fumarate Tablets.The CD4+count,human immunodeficiency virus(HIV)viral load,and biochemical indicators were compared between the two groups before treatment and at 3,6,9,and 12 months after treatment.The adherence,adverse reactions,and quality of life were also com-pared between the two groups.Results During the treatment,six patients in the observation group and 9 patients in the control group had no compliance.With the extension of treatment time,the CD4+level in both groups gradually increased,and the HIV viral load gradually decreased(P＜0.05).After 3,6,9,and 12 months of treatment,the CD4+levels in the observation group were higher than those in the control group,and the HIV viral loads were lower than those in the control group(P＜0.05).With the extension of treatment time,the levels of alanine aminotransferase,aspartate aminotransferase,urea,creatinine,and uric acid in the control group gradually increased,and the random blood glucose levels after 3,6,9,and 12 months of treatment in the control group were higher than those before treatment(P＜0.05).After 3,6,9,and 12 months of treatment,the lev-els of alanine aminotransferase,aspartate aminotransferase,urea,creatinine,uric acid,and random blood glucose in the observation group were lower than those in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 2.94％(1/34),which was lower than 90.00％(36/40)in the control group(correctedx2=55.718,P＜0.001).With the extension of treatment time,the scores of various dimensions of quality of life in both groups gradually increased,and the scores of various dimensions of quality of life after treatment in the observation group were higher than those in the control group(P＜0.05).Conclusion Compared with the free antiviral drug regimen,Elvitegravir,Cobicistat,Emtricitabine and Tenofovir Alafenamide Fumarate Tablets shows better efficacy in the treatment of AIDS-naive patients,which can significantly increase the CD4+level,and reduce the HIV viral load.Besides,it has high safety,and can significantly im-prove their quality of life.

Objective:To predict the status of microvascular invasion (MVI) in intrahepatic cholangiocarcinoma (ICC) patients preoperatively based on the radiomics analysis of contrast-enhanced CT to provide imaging evidence for early identification of patients at high risk of recurrence.Methods:Clinical data of 40 ICC patients who underwent radical hepatectomy at Nanjing Drum Tower Hospital from January 2021 to May 2024 were retrospectively collected. Patients were divided into the MVI group ( n=8) and the non-MVI group ( n=32) according to the MVI status of the postoperative pathology report. Whether there were differences in each pathological index between the groups and the efficacy of radiomics analysis of contrast-enhanced CT for the preoperative prediction of MVI were analyzed. The regions of interest (ROI) were outlined on the arterial and venous phase images using the 3D Slicer software. Then, radiomics features were extracted from each ROI based on Python. Finally, the LASSO regression and glm function were used to screen radiomics features and establish a prediction model based on the R language. The established predictive model′s diagnostic efficacy, calibration, and net clinical benefit were evaluated using the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA), respectively. Normally distributed measurement data were expressed as mean±standard deviation ( ± s) and compared using the t-test. Count data were expressed as frequency and compared using the chi-square test. Results:Patients in the MVI group had more poorly differentiated tumors and a significantly higher proportion of lymph node metastases ( P<0.05). The established radiomics prediction model included six features, 1 first-order statistical feature and 5 gray texture features. The area under the ROC curve was 0.87, the sensitivity was 75.0%, and the specificity was 90.6%. The calibration curve showed good agreement between the predicted MVI and actual MVI status, and the decision curve demonstrated that the model could provide a large net clinical benefit. Conclusion:Radiomics analysis of contrast-enhanced CT can identify the MVI status of ICC patients preoperatively and aid in clinical decision-making, providing vital evidence for individualized and precise treatment of ICC.

Objective:To compare the effects of intensive and standard blood pressure control on the outcomes of patients with acute ischemic stroke in the anterior circulation who have successfully recanalized after endovascular therapy (EVT).Methods:A multicenter, open-label, blinded-endpoint, randomized controlled design was used. Patients with anterior circulation stroke received EVT and successfully recanalized in Nanjing First Hospital, Nanjing Medical University and several branch hospitals from July 2020 to October 2022 were prospectively included. They were randomly divided into the intensive blood pressure control group (target systolic blood pressure [SBP] 100-120 mmHg) or the standard blood pressure control group (target SBP 121-140 mmHg). The blood pressure of both groups needs to achieve the target within 1 h and maintain for 72 h. The primary outcome endpoint was outcome at 90 d, and the good outcome was defined as a score of 0-2 on the modified Rankin Scale. Secondary outcome endpoints included early neurological improvement, symptomatic intracranial hemorrhage (sICH) within 24 h, and death and serious adverse events within 90 d.Results:A total of 120 patients were included, including 63 in the intensive blood pressure control group and 57 in the standard blood pressure control group. There was no statistically significant difference in baseline characteristics between the two groups. The SBP at 72 h after procedure was 122.7±8.1 mmHg in the intensive blood pressure control group and 130.2±7.4 mmHg in the standard blood pressure control group, respectively. There were no significantly differences in the good outcome rate (54.0% vs. 54.4%; χ2=0.002, P=0.963), the early neurological improvement rate (45.2% vs. 34.5%; χ2=1.367, P=0.242), the incidence of sICH (6.3% vs. 3.5%; P=0.682), mortality (7.9% vs. 14.0%; χ2=1.152, P=0.283) and the incidence of serious adverse events (12.7% vs. 15.8%; χ2=0.235, P=0.628) at 90 d between the intensive blood pressure control group and the standard blood pressure control group. Conclusion:In patients with anterior circulation stroke and successful revascularization of EVT, early intensive blood pressure control don’t improve clinical outcomes and reduce the incidence of sICH.